18:00:18 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-03 Bokslutskommuniké 2024
2024-11-01 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-06-26 ÅrsstĂ€mma 2024
2024-04-26 Ordinarie utdelning BRAIN 0.00 SEK
2024-04-15 Kvartalsrapport 2024-Q1
2024-02-29 Bokslutskommuniké 2023
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-12 Ordinarie utdelning BRAIN 0.00 SEK
2023-05-11 ÅrsstĂ€mma 2023
2023-02-28 Bokslutskommuniké 2022
2023-02-15 Extra BolagsstÀmma 2022
2022-11-30 Kvartalsrapport 2022-Q3
2022-08-31 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-12 Ordinarie utdelning BRAIN 0.00 SEK
2022-05-11 ÅrsstĂ€mma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-30 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-31 Kvartalsrapport 2021-Q1
2021-04-16 Ordinarie utdelning BRAIN 0.00 SEK
2021-04-15 ÅrsstĂ€mma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning BRAIN 0.00 SEK
2020-06-30 ÅrsstĂ€mma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-30 Kvartalsrapport 2019-Q2
2019-06-17 ÅrsstĂ€mma 2019
2019-04-08 Ordinarie utdelning BRAIN 0.00 SEK
2019-02-28 Bokslutskommuniké 2018
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-07-25 Extra BolagsstÀmma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-04-19 Ordinarie utdelning BRAIN 0.00 SEK
2018-04-18 ÅrsstĂ€mma 2018
2018-02-16 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-10 Kvartalsrapport 2017-Q2
2017-06-29 ÅrsstĂ€mma 2017
2017-05-15 Kvartalsrapport 2017-Q1
2017-04-24 Extra BolagsstÀmma 2017
2017-04-12 Ordinarie utdelning BRAIN 0.00 SEK
2017-02-14 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-14 ÅrsstĂ€mma 2016
2016-03-27 Ordinarie utdelning BRAIN 0.00 SEK
2016-01-28 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-04-28 Kvartalsrapport 2015-Q1
2015-03-27 Ordinarie utdelning BRAIN 0.00 SEK
2015-03-26 ÅrsstĂ€mma 2015
2015-01-27 Bokslutskommuniké 2014
2014-10-20 Kvartalsrapport 2014-Q3
2014-08-19 Kvartalsrapport 2014-Q2
2014-06-26 Ordinarie utdelning BRAIN 0.00 SEK
2014-06-25 ÅrsstĂ€mma 2014
2014-04-14 Extra BolagsstÀmma 2014

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHÀlsovÄrd
IndustriMedicinteknik
BrainCool Àr verksamt inom medicinteknik. Bolaget utvecklar produkter som anvÀnds inom medicinsk kylning av hjÀrnan. Teknologin Àr utvecklad som kylkuddar som appliceras pÄ olika delar av patientens kropp, dÀr systemet kontrollerar kroppstemperaturen. Produkterna anvÀnds vid behandling av olika allvarliga tillstÄnd innefattande stroke, hjÀrtstopp, samt hjÀrnskakning och migrÀn. BrainCool grundades 2010 och har sitt huvudkontor i Lund.
2023-05-13 15:15:00
  • BrainCool has signed a purchase agreement with a healthcare system covering 74 hospitals in the southeastern United States.
  • The purchase agreement relates to IQoolℱ System and was signed after the system demonstrated a number of clinical and economic advantages over competing systems.
  • The intention is to establish at least 20 products during the term of the agreement (1 year).

BrainCool AB (the "Company") has signed a one-year purchase agreement with Vanderbilt Health, based in Nashville, Tennessee after the product IQoolℱ System has been evaluated against competing systems. The parties intend to establish the product for the healthcare system's hospitals in the southeastern United States.
 
The company already has an agreement with the national purchasing organization GPO Healthtrust (see press release 2020-06-17, https://www.braincool.se/17/28/post/?slug=braincool-ab-publ-ingar-inkopsavtal-med-healthtrust-50650ee4). In 2022, a group buy project with Healthtrust was also carried out as part of establishing IQoolℱ System within HCA Healthcare, one of the largest healthcare systems in the United States.
 
CEO Martin Waleij's comments
 
– Under the agreement, Vanderbilt Health plans to offer our product to all hospitals in the group in the coming year, subject to similar terms that we have established with GPO Healthtrust in 2023. This is after an evaluation that showed a number of clinical and economic benefits of IQool's product offering. The goal is to establish at least 20 systems during the term of the agreement.
 
In 2023, BrainCool has strengthened its sales organization in Texas, Chicago and Tennessee and has a clear goal to grow in these regions and establish the product to a greater extent in additional US healthcare systems. Our establishment in Tennessee now embodies the efforts in the southeastern United States, but should also be seen in the light of the fact that major players such as Healthtrust, HCA Healthcare and Vanderbilt have their headquarters in Nashville.
 
Continued growth in the US market
In addition to the new agreement with Vanderbilt Health, BrainCool has continued to grow in other healthcare systems in 2023, including two additional hospitals within Jefferson Health purchasing two systems each. (for more information about Jefferson Health, see press release 2021-10-19 https://www.braincool.se/17/28/post/?slug=braincool-ab-publ-ny-viktig-order-i-usa-for-iqool-system-86fa71ef).